幼年犬药物性关节病：恶喹酸和吡哌酸所致关节病变的临床病理研究 - Suppr

Suppr

超能文献

Juvenile canine drug-induced arthropathy: clinicopathological studies on articular lesions caused by oxolinic and pipemidic acids.

作者信息

Gough A, Barsoum N J, Mitchell L, McGuire E J, de la Iglesia F A

出版信息

Toxicol Appl Pharmacol. 1979 Oct;51(1):177-87. doi: 10.1016/0041-008x(79)90020-6.

DOI:10.1016/0041-008x(79)90020-6

PMID:524369

Abstract

摘要

相似文献

Juvenile canine drug-induced arthropathy: clinicopathological studies on articular lesions caused by oxolinic and pipemidic acids.

Toxicol Appl Pharmacol. 1979 Oct;51(1):177-87. doi: 10.1016/0041-008x(79)90020-6.

Evaluation of the DNA-damaging and mutagenic activity of oxolinic and pipemidic acids by the granuloma pouch assay.

Mutagenesis. 1988 Sep;3(5):397-401. doi: 10.1093/mutage/3.5.397.

Toxicological studies on pipemidic acid. V. Effect on diarthrodial joints of experimental animals.

J Toxicol Sci. 1978 Nov;3(4):357-67. doi: 10.2131/jts.3.357.

Fine structural changes during reparative phase of canine drug-induced arthropathy.

Vet Pathol. 1985 Jan;22(1):82-4. doi: 10.1177/030098588502200113.

Quinolone-induced arthropathy in the neonatal mouse. Morphological analysis of articular lesions produced by pipemidic acid and ciprofloxacin.

Fundam Appl Toxicol. 1995 Nov;28(1):59-64. doi: 10.1006/faat.1995.1146.

[Treatment of urinary infections in gynecology. Comparative study of norfloxacin, oxolinic acid and pipemidic acid carried out on ambulatory patients].

Minerva Urol Nefrol. 1987 Oct-Dec;39(4):383-9.

[A comparison of the effects of three urinary infection chemotherapeutics - nalidixic, oxolinic, and pipemidic acids (author's transl)].

Cas Lek Cesk. 1979 May 11;118(19):588-92.

Metabolites of pipemidic acid in human urine.

Xenobiotica. 1980 Jan;10(1):37-46. doi: 10.3109/00498258009033729.

Effect of nalidixic acid, pipemidic acid and cinoxacin on chondrocyte metabolism in explants of articular cartilage.

Clin Exp Rheumatol. 1990 Jul-Aug;8(4):393-5.

Cross resistance of quinolone derivatives in gram-negative bacteria.

Chemioterapia. 1985 Apr;4(2):192-6.

引用本文的文献

Safety analysis of quinolones use in minors-based on the FAERS database.

Front Med (Lausanne). 2024 Aug 29;11:1437376. doi: 10.3389/fmed.2024.1437376. eCollection 2024.

Pharmacokinetics and Optimal Dosing of Levofloxacin in Children for Drug-Resistant Tuberculosis: An Individual Patient Data Meta-Analysis.

Clin Infect Dis. 2024 Mar 20;78(3):756-764. doi: 10.1093/cid/ciae024.

A tool for screening potentially inappropriate prescribing in Chinese children.

Front Pharmacol. 2022 Oct 31;13:1019795. doi: 10.3389/fphar.2022.1019795. eCollection 2022.

Safety of Quinolones in Children: A Systematic Review and Meta-Analysis.

Paediatr Drugs. 2022 Sep;24(5):447-464. doi: 10.1007/s40272-022-00513-2. Epub 2022 Jun 30.

Recent Trends in the Epidemiology, Diagnosis, and Treatment of Macrolide-Resistant .

J Clin Med. 2022 Mar 24;11(7):1782. doi: 10.3390/jcm11071782.

Fluoroquinolone and no risk of Achilles-tendinopathy in childhood pneumonia under eight years of age-a nationwide retrospective cohort.

J Thorac Dis. 2021 Jun;13(6):3399-3408. doi: 10.21037/jtd-20-2256.

Real-world safety evaluation of musculoskeletal adverse events associated with Korean pediatric fluoroquinolone use: a nationwide longitudinal retrospective cohort study.

Sci Rep. 2019 Dec 27;9(1):20156. doi: 10.1038/s41598-019-56815-y.

Benefits and risks of therapeutic alternatives for macrolide resistant Mycoplasma pneumoniae pneumonia in children.

Korean J Pediatr. 2019 Jun;62(6):199-205. doi: 10.3345/kjp.2018.07367. Epub 2019 Mar 15.

Safety Concerns Surrounding Quinolone Use in Children.

J Clin Pharmacol. 2016 Sep;56(9):1060-75. doi: 10.1002/jcph.715. Epub 2016 Mar 28.

Pharmacokinetics and Safety of Ofloxacin in Children with Drug-Resistant Tuberculosis.

Antimicrob Agents Chemother. 2015 Oct;59(10):6073-9. doi: 10.1128/AAC.01404-15. Epub 2015 Jul 20.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Juvenile canine drug-induced arthropathy: clinicopathological studies on articular lesions caused by oxolinic and pipemidic acids.

作者信息

Gough A, Barsoum N J, Mitchell L, McGuire E J, de la Iglesia F A

出版信息

Toxicol Appl Pharmacol. 1979 Oct;51(1):177-87. doi: 10.1016/0041-008x(79)90020-6.

DOI:10.1016/0041-008x(79)90020-6

PMID:524369

Abstract

摘要

相似文献

Juvenile canine drug-induced arthropathy: clinicopathological studies on articular lesions caused by oxolinic and pipemidic acids.

Toxicol Appl Pharmacol. 1979 Oct;51(1):177-87. doi: 10.1016/0041-008x(79)90020-6.

Evaluation of the DNA-damaging and mutagenic activity of oxolinic and pipemidic acids by the granuloma pouch assay.

Mutagenesis. 1988 Sep;3(5):397-401. doi: 10.1093/mutage/3.5.397.

Toxicological studies on pipemidic acid. V. Effect on diarthrodial joints of experimental animals.

J Toxicol Sci. 1978 Nov;3(4):357-67. doi: 10.2131/jts.3.357.

Fine structural changes during reparative phase of canine drug-induced arthropathy.

Vet Pathol. 1985 Jan;22(1):82-4. doi: 10.1177/030098588502200113.

Quinolone-induced arthropathy in the neonatal mouse. Morphological analysis of articular lesions produced by pipemidic acid and ciprofloxacin.

Fundam Appl Toxicol. 1995 Nov;28(1):59-64. doi: 10.1006/faat.1995.1146.

[Treatment of urinary infections in gynecology. Comparative study of norfloxacin, oxolinic acid and pipemidic acid carried out on ambulatory patients].

Minerva Urol Nefrol. 1987 Oct-Dec;39(4):383-9.

[A comparison of the effects of three urinary infection chemotherapeutics - nalidixic, oxolinic, and pipemidic acids (author's transl)].

Cas Lek Cesk. 1979 May 11;118(19):588-92.

Metabolites of pipemidic acid in human urine.

Xenobiotica. 1980 Jan;10(1):37-46. doi: 10.3109/00498258009033729.

Effect of nalidixic acid, pipemidic acid and cinoxacin on chondrocyte metabolism in explants of articular cartilage.

Clin Exp Rheumatol. 1990 Jul-Aug;8(4):393-5.

Cross resistance of quinolone derivatives in gram-negative bacteria.

Chemioterapia. 1985 Apr;4(2):192-6.

引用本文的文献

Safety analysis of quinolones use in minors-based on the FAERS database.

Front Med (Lausanne). 2024 Aug 29;11:1437376. doi: 10.3389/fmed.2024.1437376. eCollection 2024.

Pharmacokinetics and Optimal Dosing of Levofloxacin in Children for Drug-Resistant Tuberculosis: An Individual Patient Data Meta-Analysis.

Clin Infect Dis. 2024 Mar 20;78(3):756-764. doi: 10.1093/cid/ciae024.

A tool for screening potentially inappropriate prescribing in Chinese children.

Front Pharmacol. 2022 Oct 31;13:1019795. doi: 10.3389/fphar.2022.1019795. eCollection 2022.

Safety of Quinolones in Children: A Systematic Review and Meta-Analysis.

Paediatr Drugs. 2022 Sep;24(5):447-464. doi: 10.1007/s40272-022-00513-2. Epub 2022 Jun 30.

Recent Trends in the Epidemiology, Diagnosis, and Treatment of Macrolide-Resistant .

J Clin Med. 2022 Mar 24;11(7):1782. doi: 10.3390/jcm11071782.

Fluoroquinolone and no risk of Achilles-tendinopathy in childhood pneumonia under eight years of age-a nationwide retrospective cohort.

J Thorac Dis. 2021 Jun;13(6):3399-3408. doi: 10.21037/jtd-20-2256.

Real-world safety evaluation of musculoskeletal adverse events associated with Korean pediatric fluoroquinolone use: a nationwide longitudinal retrospective cohort study.

Sci Rep. 2019 Dec 27;9(1):20156. doi: 10.1038/s41598-019-56815-y.

Benefits and risks of therapeutic alternatives for macrolide resistant Mycoplasma pneumoniae pneumonia in children.

Korean J Pediatr. 2019 Jun;62(6):199-205. doi: 10.3345/kjp.2018.07367. Epub 2019 Mar 15.

Safety Concerns Surrounding Quinolone Use in Children.

J Clin Pharmacol. 2016 Sep;56(9):1060-75. doi: 10.1002/jcph.715. Epub 2016 Mar 28.

Pharmacokinetics and Safety of Ofloxacin in Children with Drug-Resistant Tuberculosis.

Antimicrob Agents Chemother. 2015 Oct;59(10):6073-9. doi: 10.1128/AAC.01404-15. Epub 2015 Jul 20.